The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma
Clinical trial NCT04415385 · UNKNOWN
Trial details
- NCT number
- NCT04415385
- Sponsor
- Zhejiang Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-01
- Primary completion
- 2022-06-01
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.